GE HealthCare stock upgraded to buy on improved outlook

On Wednesday, GE HealthCare (NASDAQ:GEHC) Technologies Inc. (NASDAQ: GEHC) shares received an upgraded rating from Neutral to Buy with a new price target of $100.00, as announced by a BTIG analyst. The upgrade comes after a challenging first half of 2024, especially due to market dynamics in China that negatively impacted the company's performance. Nonetheless, the analyst sees a favorable setup for the company moving into the second half of the year.

The firm has adjusted its guidance for the full year 2024, acknowledging a greater than 20% decline in the Chinese market, as revealed during the second-quarter earnings call. This revised outlook sets a lower performance threshold for the company as it enters the latter half of the year.

The analyst's optimism is further bolstered by the potential for GE HealthCare to outperform in the upcoming quarters, particularly in the first half of 2025, which is expected to present easier comparative figures.

The positive sentiment is also driven by insights from a recent meeting with GE HealthCare's management during the summer. The management indicated that 75% of what is needed to achieve second-half 2024 targets is already present in the company's backlog. This, coupled with a robust capital equipment environment in the United States, particularly within the Imaging sector, suggests that GE HealthCare is well-positioned to exceed expectations in the second half of the year.

Furthermore, the analyst anticipates that the upcoming Analyst Day will provide an opportunity for GE HealthCare to reaffirm its long-term goals and offer more detailed plans on achieving sustainable mid-single-digit top-line growth and operating margin expansion (OMX). This event is expected to boost investor confidence in the company's future prospects.

With these factors in mind, the analyst concludes that GE HealthCare is poised for a strong performance in the second half of 2024, leading to the decision to upgrade the stock and establish a higher price target.

In other recent news, GE HealthCare Technologies Inc. has been in the spotlight with several significant developments. The company initiated a secondary underwritten public offering of 10 million shares of its common stock, with Morgan Stanley & Co. LLC and Citigroup leading the offering. This is not a sale by GE HealthCare, hence the company will not receive any proceeds from this transaction.

Furthermore, GE HealthCare has issued $1 billion in senior unsecured notes with an interest rate of 4.8% due in 2029. The company also reported Q2 revenues of $4.84 billion and earnings per share of $1.00, nearly matching Wall Street expectations. This performance was primarily driven by strong results in the Pharmaceutical Diagnostics segment and robust U.S. demand, leading to a 3% growth in orders.

In addition, a recent study demonstrated the effectiveness of GE HealthCare's End-tidal Control software in delivering inhaled anesthesia, showing potential in reducing anesthetic agent usage, which could lead to lower greenhouse gas emissions and costs.

Analysts from JPMorgan and Piper Sandler have also weighed in on the company's prospects. JPMorgan initiated coverage on GE HealthCare with a Neutral rating and a price target of $90.00, while Piper Sandler raised the stock's price target from $92.00 to $95.00, maintaining an Overweight rating.

Despite market headwinds, particularly in China, GE HealthCare reported modest organic revenue growth and a 3% increase in orders for Q2 2024. The company maintained its EPS guidance for the year, raised its guidance for adjusted earnings before interest and taxes margin expansion but lowered its full-year 2024 organic revenue growth guidance to 1-2% due to temporary market headwinds in China. These are the recent developments in GE HealthCare Technologies' business operations.

InvestingPro Insights

As GE HealthCare Technologies Inc. (NASDAQ: GEHC) navigates through the complexities of the market, particularly the challenges in China, it's important to consider the company's financial health and market position. According to InvestingPro data, GE HealthCare boasts a market capitalization of $39.63 billion and a Price/Earnings (P/E) ratio of 24.55, which adjusts slightly to 25.02 when considering the last twelve months as of Q2 2024. This valuation comes in the context of a revenue growth of 2.52% over the same period, indicating a steady financial trajectory.

InvestingPro Tips highlight GE HealthCare's low price volatility and its status as a prominent player in the Healthcare Equipment & Supplies industry. These factors, along with the company's profitability over the last twelve months and analysts' predictions of profitability for this year, suggest a stable investment. However, it is worth noting that 11 analysts have revised their earnings downwards for the upcoming period, which may warrant attention from investors.

For those looking to delve deeper into the financial metrics and future outlook of GE HealthCare, additional InvestingPro Tips are available at https://www.investing.com/pro/GEHC. With a comprehensive set of data and insights, investors can better assess the potential of GE HealthCare as it aims to achieve its targets in the latter half of 2024 and beyond.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.